Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

키워드

참고문헌 (20)

1. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
2. Kim D, "Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease", Liver Int, 39, pp.332~341 (2019)
3. Eunji Ko, "Risk factors in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.79~85 (2023), 대한간학회
4. Kim D, "Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.132~138 (2016)
5. Hsieh YC, "Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression", Clin Gastroenterol Hepatol, 21, pp.388~397 (2023)
6. Riazi K, "The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
7. Balakrishnan M, "Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men : A systematic review and meta-analysis", Clin Gastroenterol Hepatol, 19, pp.61~71 (2021)
8. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
9. Koo BK, "Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 33, pp.1277~1285 (2018)
10. Koo BK, "Long-term effect of PNPLA3 on the aggravation of nonalcoholic fatty liver disease in the biopsy-proven cohort", Clin Gastroenterol Hepatol, 21, pp.1105~1107 (2023)
11. Yoo T, "Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in nonalcoholic fatty liver disease", J Hepatol, 75, pp.514~523 (2021)
12. Kim D, "Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis", J Gastroenterol, 55, pp.330~341 (2020)
13. Jung Y, "Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 52, pp.1603~1614 (2020)
14. Jung Y, "Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus", Liver Int, 41, pp.2892~2902 (2021)
15. Kang S, "Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease : a Korean nationwide survey", J Cachexia Sarcopenia Muscle, 11, pp.1232~1241 (2020)
16. Hsieh YC, "Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease", Liver Int, 41, pp.494~504 (2021)
17. Moon JH, "Non-alcoholic fatty liver disease and sarcopenia additively increase mortality : a Korean nationwide survey", J Cachexia Sarcopenia Muscle, 12, pp.964~972 (2021)
18. Lee G, "Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD", Nat Commun, 11, pp.4982~ (2020)
19. Byeonggeun Kang, "The Chromatin Accessibility Landscape of Nonalcoholic Fatty Liver Disease Progression", Molecules and Cells, 45(5), pp.343~352 (2022), 한국분자세포생물학회[DOI]
20. Shin HK, "Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease", Sci Rep, 11, pp.18004~ (2021)

관련 논문AI추천